Channing J. Paller, M.D, is Assistant Professor of Oncology at the Johns Hopkins University School of Medicine focusing on translational research and clinical trials of developmental therapeutics in prostate and other solid tumors. She treats patients at both Hopkins Sibley Memorial Hospital in Washington and at the Sidney Kimmel Comprehensive Cancer Center in Baltimore. Dr. Paller completed her M.D. training at Harvard Medical School, her medical residency in Internal Medicine at the Johns Hopkins Hospital, and her Fellowship in Medical Oncology at the Johns Hopkins Kimmel Cancer Center.
Dr. Paller’s research focuses on the evaluation of new therapies for prostate cancer, particularly combination therapies that engage the immune system. She actively participates in the Johns Hopkins Kimmel Cancer Center Phase I program, and complements her work on immunology with trials rigorously evaluating natural products. She is the Principal Investigator on two multi-site clinical trials including one evaluating a combination of an approved therapy with a novel inhibitor of TGF-BETA that has shown promise both in retarding metastases and enabling improved immune response. She was the first author on the recently published Consensus Recommendations on the Phase I Combination Clinical Trials of the Clinical Trial Design Task Force of the Investigational Drug Steering Committee of the National Cancer Institute and she chaired the Oral Abstract Session on Genitourinary (Prostate) Cancer at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO). She also received the 2015 Passano Clinician Scientist Award recognizing “a young scientist whose work, though in the early stages, already contributes to scientific research.”
During her training, Dr. Paller gained an understanding of the regulatory aspects of experimental therapeutics through a rotation with the Chief of the Investigational Drug Branch at the NCI Cancer Therapy Evaluation Program, as well as with the Food and Drug Administration on rotation with the Associate Director for Regulatory Science in the Office of Oncology Drug Products. Earlier in her training she served rotations at the Weizmann Institute in Israel’s Department of Biological Regulation, at Massachusetts General Hospital’s Endocrine Unit, and at McCord Hospital in South Africa, where she participated in the Harvard AIDS project.